DUBLIN--(BUSINESS WIRE)--The "Premature Ejaculation - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Premature Ejaculation - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Premature Ejaculation (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Premature Ejaculation (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.
Premature Ejaculation (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Premature Ejaculation (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Premature Ejaculation (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
- Report Coverage
Premature Ejaculation - Overview
Premature Ejaculation - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Premature Ejaculation - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Premature Ejaculation - Companies Involved in Therapeutics Development
- Ctcbio Inc
- Dicot AB
- Ixchelsis Ltd
- NeuroHealing Pharmaceuticals Inc
- Plethora Solutions Holdings Plc
Premature Ejaculation - Drug Profiles
(clomipramine hydrochloride + sildenafil citrate) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
(lidocaine + prilocaine) - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
cligosiban - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
libiguins - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
modafinil - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Premature Ejaculation - Dormant Projects
Premature Ejaculation - Discontinued Products
Premature Ejaculation - Product Development Milestones
- Featured News & Press Releases
- Jul 23, 2020: CHMP recommended a change in classification status for Fortacin
- Sep 19, 2019: Plethora Pharma Solutions receives CHMP positive opinion for Senstend
- Jul 11, 2018: Dicot signs extended Service Agreement with Anthem Biosciences for Preclinical Development of Libiguin
- Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation
- Nov 11, 2014: Plethora Solutions Provides Company Update
- Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU
- Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment
- Mar 11, 2014: Plethora Solutions Provides Company update
- Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation
- Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation
- Jul 01, 2013: AGM Statement & PSD502 Regulatory Update
- Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update
- Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502
- Dec 19, 2011: Plethora Provides Update On PSD502
- Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/h8x37x
